For the estimated one in ten women of reproductive age living with endometriosis, the path to a diagnosis is often a surgical odyssey. The gold standard for confirming the disease remains a laparoscopy, an invasive procedure that carries surgical risks, recovery time, and significant cost. Afynia, a Canadian biotech spinout from McMaster University, is betting that a simple blood draw can change that standard of care [TechCrunch, February 2025].
Founded in 2021 by researcher Lauren Foster and her former PhD student Jocelyn Wessels, the company is developing EndomiR, a patented, non-invasive diagnostic test that analyzes microRNA signatures in the blood to detect endometriosis [Afynia: EndomiR, retrieved 2026]. The technology, stemming from academic work on ovarian regulation that began around 2015, represents a quiet but potentially profound shift in how a chronic and often debilitating condition is identified [TechCrunch, February 2025].
The diagnostic wedge
The clinical promise of Afynia's approach is its potential to sidestep the diagnostic bottleneck. Today, the average delay from symptom onset to diagnosis is between 7 to 10 years, a period marked by pain, infertility, and repeated medical consultations. A reliable, accessible blood test could dramatically compress that timeline, allowing for earlier intervention and management. The company reports its test is already being used in several Canadian fertility clinics as part of a pilot market launch, a critical first step in gathering real-world validation [The Forge, McMaster University, Unknown].
From a regulatory and commercial standpoint, the non-invasive nature of the test is a key wedge. It avoids the high procedural bar of surgical diagnostics, potentially enabling a smoother path to clinical adoption and reimbursement. The test is positioned as a B2B diagnostic tool for clinics, not a direct-to-consumer wellness product, which aligns with the rigorous evidence requirements of healthcare systems.
A strategic seed round
In February 2025, Afynia secured a $5 million seed round to advance its commercial and clinical efforts. The round was led by Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics, with participation from Impact America Fund, SOSV, Capital Angel Network, and Gaingels [TechCrunch, February 2025]. This was preceded by approximately $1.5 million in pre-seed funding from a consortium including McMaster University and SOSV [TechCrunch, February 2025].
The lead investor is a significant signal. Bio-Rad's involvement suggests more than just financial backing; it implies a strategic partnership that could provide Afynia with deep expertise in assay development, manufacturing, and global distribution channels for regulated diagnostics.
Pre-seed (Unknown) | 1.5 | M USD
Seed (Feb 2025) | 5 | M USD
The academic founding team
The company's origins are firmly rooted in the lab. Co-founder and CEO Lauren Foster is the researcher whose work on ovarian regulation and microRNA forms the scientific foundation of EndomiR [TechCrunch, February 2025]. Her professional background also includes roles in sustainable finance at Bloomberg and communications leadership at the CFA Institute, which may lend commercial and strategic depth to the scientific core [LinkedIn Profile: Lauren Foster, retrieved 2026]. Co-founder and Chief Scientific Officer Jocelyn Wessels was Foster's PhD student, ensuring the founding team's technical continuity from academic discovery to commercial application [TechCrunch, February 2025].
As a university spinout, Afynia benefits from the institutional support of McMaster, which participated in its early funding. The company reported a headcount of nine employees as of 2026 [PitchBook, retrieved 2026]. This small, focused team reflects the capital-intensive, research-driven early stage of a novel diagnostic developer.
The validation challenge ahead
The ambition is clear, but the road for any new diagnostic is paved with rigorous validation. The company's most immediate task is to generate robust clinical data from its pilot deployments to demonstrate the test's sensitivity, specificity, and real-world utility. Peer-reviewed publications will be a crucial milestone for building credibility with the broader medical community, a step that has not yet been publicly reported.
Furthermore, while a blood-based test is less invasive, it must prove it is not less accurate. It will need to show it can reliably detect the diverse presentations and stages of endometriosis, a disease known for its heterogeneity. The competitive landscape for non-invasive endometriosis diagnostics, while not detailed in public sources, is likely to attract other players as the market potential becomes clearer.
Afynia's most plausible answer to these challenges lies in its focused pilot strategy and its strategic investor. By embedding its test in fertility clinics,settings where endometriosis is a frequent concern,the company can gather targeted, relevant data. Bio-Rad's resources can help navigate the complex pathway toward regulatory clearances, such as FDA approval or CE marking, which will be essential for scaling.
What a new standard could mean
For patients with endometriosis, the standard of care today is a paradox. To confirm the disease, they must often undergo an expensive and invasive surgical procedure that many clinicians are hesitant to recommend without strong preliminary evidence. This creates a diagnostic catch-22 that prolongs suffering. Treatment, which can include hormonal therapies, pain management, or eventually surgery for disease removal, is often initiated late.
Afynia's bet is that by offering a low-friction, objective diagnostic tool, it can break this logjam. A successful blood test would not only accelerate diagnosis for individuals but could also transform endometriosis from a surgical diagnosis to a laboratory-managed one, changing referral patterns, research protocols, and ultimately, the patient experience. The next twelve months will be telling, as data from the ongoing clinic pilots must translate into the clinical evidence required to convince payers and guide wider adoption. If the microRNA signatures hold up, a vial of blood may one day replace the scalpel for thousands of women seeking answers.
Sources
- [TechCrunch, February 2025] University spin-out Afynia secures $5M seed to commercialize its microRNA panel test for endometriosis | https://techcrunch.com/2025/02/25/university-spin-out-afynia-secures-5m-seed-to-commercialize-its-microrna-panel-test-for-endometriosis/
- [Afynia, retrieved 2026] EndomiR | https://afynia.com/
- [The Forge, McMaster University, Unknown] Media | https://afynia.com/media
- [LinkedIn Profile: Lauren Foster, retrieved 2026] Lauren Foster - Senior Director of Communications at CFA Institute | https://www.linkedin.com/in/lauren-foster/
- [PitchBook, retrieved 2026] Afynia Company Profile | https://pitchbook.com/profiles/company/529850-35